Skip To Main Content
Veronica Mollica on Muck Rack

Veronica Mollica

As seen in: Nature, MDPI, Taylor & Francis Online, JAMA Oncology, The Lancet, Future Medicine, European Urology, Lung Cancer, TechTrends
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Veronica

Contact Veronica, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

PSMA-PET imaging in prostate cancer patients with high-risk biochemical recurrence: implications from an “EMBARK-Like” cohort - Prostate Cancer and Prostatic Diseases

|
By Matteo Droghetti, Francesco Ceci, Andrea Farolfi, Matteo Bauckneht, Francesco Lanfranchi, Andrea Di Giorgio, Paolo Castellucci, Carlos Artigas, José Leite, Paola Corona, Qaid Ahmed Shagera, Renata Moreira, Christian Gonzalez, Christian González Verified, Marcelo Queiroz, Guido Rovera, Desiree Deandreis, Sara Tamburini, Pietro Piazza, Angelo Mottaran, Veronica Mollica, Francesco Massari, Stefano Fanti, Lorenzo Bianchi, Riccardo Schiavina, Valerio Pirelli, Felipe de Galiza Barbosa, Lorenzo Nanni, Federico Bevilacqua
| Nature Verified
Abstract The EMBARK trial demonstrated improved survival with enzalutamide plus androgen deprivation therapy (ADT) in non-metastatic hormone-sensitive prostate cancer patients with high-risk biochemical recurrence (BCR), although staged using conventional imaging. Given the higher sensitivity of PSMA-PET, many of these patients could harbor metastatic disease. We retrospectively analyzed 587 patients with first BCR after radical treatment who underwent PSMA-PET.
Open in Who Shared Issue with article?

Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges

|
By Elisa Tassinari, Andrea Marchetti, Veronica Mollica, Linda Danielli
| Taylor & Francis Online
ABSTRACT Introduction Prostate cancer represents a significant oncological challenge, with its natural history predominantly driven by androgen receptor (AR) signaling. The pivotal role of this pathway underscores the rationale for targeting AR activity in therapeutic strategies. However, the development of resistance mechanisms has highlighted the need for advanced therapies to address the complexity of the castration-resistant status.
Open in Who Shared Issue with article?

Adjuvant treatment in renal cell carcinoma: a never-ending story?

|
By Veronica Mollica, IRCCS Azienda Ospedaliero, Francesco Massari
| The Lancet Verified
The CheckMate 914 trial1 assessed the role of nivolumab plus ipilimumab compared with double placebo in the adjuvant setting in patients with localised renal cell carcinoma (RCC). The experimental treatment did not reach its primary endpoint of disease-free survival (DFS) with a hazard ratio (HR) of 0·92 (95% CI 0·71–1·19; p=0·53).
Open in Who Shared Issue with article?
See all 27 licensed articles (29 Total)